BioSpace News Archive

The drug for treatment-resistant depression reportedly demonstrated significant improvement in patients at its highest dose of 25 mg. Here’s more about it.

Cell therapy veteran Christina Coughlin is taking over the reins of the privately-held company developing natural killer immune cells to battle cancer.

A research team at the University of North Carolina – Chapel Hill (UNC) and Duke University, in Durham, NC identified an antibody that attacks SARS-CoV-2 and its variants and other types of coronaviruses.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

Acasti Pharma Inc., provided a business update and announced its operating and financial results for the second quarter of fiscal 2022 ended September 30, 2021.

Ikena Oncology, Inc., a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, announced financial results for the quarter ended September 30, 2021.

TScan Therapeutics, Inc., a biopharmaceutical company focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer, reported financial results for the quarter ended September 30, 2021, highlighted recent program progress, and outlined key upcoming expected milestones.

Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, reported financial results for the three and nine months ended September 30, 2021 and provided a general business update.

Arvinas, Inc., a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, announced that Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16 at 10:40 a.m. ET.

Anavex Life Sciences Corp. announced that its President and Chief Executive Officer, Christopher U. Missling, PhD, will join the panel, “Exploring the Promise of Novel Therapeutic Approaches,” at the Lausanne VIII Workshop on Wednesday, November 17th at 10:00 a.m. EST to 11:00 a.m. EST.